ArticleInternational journal of hematology2008
Chromatin regulation by AML1 complex.
Article in International journal of hematology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Runx Transcription Factors in T Cells-What Is Beyond Thymic Development?Frontiers in immunology · 2021Review
- RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia.International journal of molecular sciences · 2019Review
- MicroRNA 665 Regulates Dentinogenesis through MicroRNA-Mediated Silencing and Epigenetic Mechanisms.Molecular and cellular biology · 2015Article
- KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.Neoplasia (New York, N.Y.) · 2014Article
- Transcription factor Runx3 regulates interleukin-15-dependent natural killer cell activation.Molecular and cellular biology · 2014Article
- Review
- Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity.Haematologica · 2013Article
- Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.International journal of hematology · 2013Article
- Tyrosyl phosphorylation toggles a Runx1 switch.Genes & development · 2012Article
- Article
- Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis.Cancer science · 2008Review
- Post-translational modifications of Runx1 regulate its activity in the cell.Blood cells, molecules & diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The AML1 gene is the most frequent target of chromosomal translocations in acute leukemias. AML1 is essential for definitive hematopoiesis and regulates transcription of its target genes by binding to the specific DNA sequence. AML1 forms large multiprotein complexes including CBFbeta as a "core component" as well as several classes of chromatin modulators such as p300/CBP, MOZ, PML and HIPK2 as "regulatory complex". In this review, we describe the mechanisms by which AML1 complex regulates gene transcription and hematopoiesis, and its disruption by the leukemia-associated chromosomal translocations that affect genes for components of AML1 complex in view of deregulation of chromatin structure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.